A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Clinical trial NCT02413827 · TERMINATED
Trial details
- NCT number
- NCT02413827
- Sponsor
- Celldex Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-01
- Primary completion
- 2016-11-02
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.